Literature DB >> 23734370

Reply to S. Buti and S. Culine.

Yu-Ning Wong, Elizabeth R Plimack, Samuel Litwin, David Vaughn, James Lee, Wei Song, Gary R Hudes.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23734370      PMCID： PMC3625713          DOI： 10.1200/JCO.2012.47.8255

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Cetuximab in advanced bladder cancer.

Authors:  Stéphane Culine
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

2.  Does the cetuximab plus paclitaxel combination deserve to be studied in a phase III trial?

Authors:  Sebastiano Buti
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

3.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.

Authors:  Yaoting Gui; Guangwu Guo; Yi Huang; Xueda Hu; Aifa Tang; Shengjie Gao; Renhua Wu; Chao Chen; Xianxin Li; Liang Zhou; Minghui He; Zesong Li; Xiaojuan Sun; Wenlong Jia; Jinnong Chen; Shangming Yang; Fangjian Zhou; Xiaokun Zhao; Shengqing Wan; Rui Ye; Chaozhao Liang; Zhisheng Liu; Peide Huang; Chunxiao Liu; Hui Jiang; Yong Wang; Hancheng Zheng; Liang Sun; Xingwang Liu; Zhimao Jiang; Dafei Feng; Jing Chen; Song Wu; Jing Zou; Zhongfu Zhang; Ruilin Yang; Jun Zhao; Congjie Xu; Weihua Yin; Zhichen Guan; Jiongxian Ye; Hong Zhang; Jingxiang Li; Karsten Kristiansen; Michael L Nickerson; Dan Theodorescu; Yingrui Li; Xiuqing Zhang; Songgang Li; Jian Wang; Huanming Yang; Jun Wang; Zhiming Cai
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

4.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

Authors:  Joaquim Bellmunt; Toni K Choueiri; Ronan Fougeray; Fabio A B Schutz; Yacine Salhi; Eric Winquist; Stéphane Culine; Hans von der Maase; David J Vaughn; Jonathan E Rosenberg
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

5.  Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Authors:  Nuria Juanpere; Laia Agell; Marta Lorenzo; Silvia de Muga; Laura López-Vilaró; Raquel Murillo; Sergi Mojal; Sergio Serrano; José A Lorente; Josep Lloreta; Silvia Hernández
Journal:  Hum Pathol       Date:  2012-03-12       Impact factor: 3.466

6.  Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Authors:  Guru Sonpavde; Gregory R Pond; Ronan Fougeray; Toni K Choueiri; Angela Q Qu; David J Vaughn; Guenter Niegisch; Peter Albers; Nicholas D James; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Awais Khan; Nicholas J Vogelzang; Tomasz M Beer; Walter M Stadler; Peter H O'Donnell; Cora N Sternberg; Jonathan E Rosenberg; Joaquim Bellmunt
Journal:  Eur Urol       Date:  2012-11-26       Impact factor: 20.096

7.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

Authors:  Yu-Ning Wong; Samuel Litwin; David Vaughn; Seth Cohen; Elizabeth R Plimack; James Lee; Wei Song; Michael Dabrow; Marion Brody; Holly Tuttle; Gary Hudes
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

8.  A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Authors:  Gottfrid Sjödahl; Martin Lauss; Sigurdur Gudjonsson; Fredrik Liedberg; Christer Halldén; Gunilla Chebil; Wiking Månsson; Mattias Höglund; David Lindgren
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.